FDA Approved: NEXAVAR — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved a supplemental application for Nexavar (sorafenib) submitted by Bayer HealthCare Pharmaceuticals Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Carcinoma
• Hepatocellular Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

SUPPL AP for NEXAVAR (SORAFENIB)